Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double Blind, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The efficacy and tolerability of vilazodone, a combined selective serotonin reuptake inhibitor and partial 5-hydroxytryptamine-1A (5-HT(1A)) receptor agonist, were evaluated in adult patients with major depressive disorder (MDD). METHOD: This was a randomized, double-blind, placebo-controlled trial conducted from February 2006 to May 2007. Patients aged 18 through 65 years with MDD (DSM-IV criteria) and a baseline 17-item Hamilton Rating Scale for Depression (HAM-D-17) score of >or= 22 were randomly assigned to vilazodone or placebo for 8 weeks. Vilazodone was titrated from 10 mg to 40 mg once a day over 2 weeks. Efficacy was assessed by mean change from baseline to week 8 on the Montgomery-Asberg Depression Rating Scale (MADRS), HAM-D-17, and Hamilton Rating Scale for Anxiety. Response rates were determined at week 8 for the MADRS, HAM-D-17, and Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales. Data were analyzed using a modified last-observation-carried-forward method in the intention-to-treat (ITT) sample. The Arizona Sexual Experience Scale (ASEX) was also measured at baseline and week 8. RESULTS: Of 410 randomly assigned patients, 198 receiving vilazodone and 199 receiving placebo were included in the ITT population. The mean changes in MADRS and HAM-D-17 total scores from baseline to week 8 were significantly (p = .001 and p = .022, respectively) greater with vilazodone than with placebo. Significant (p < .05) improvements in MADRS and HAM-D-17 scores were noted at week 1, the earliest time point measured. Response rates were significantly higher with vilazodone than with placebo on the MADRS (p = .007), HAM-D-17 (p = .011), and CGI-I (p = .001). Treatment-emergent adverse events with vilazodone included diarrhea, nausea, and somnolence; most adverse events were of mild or moderate intensity. There were no clinically significant differences for either gender in ASEX scores at end of treatment. CONCLUSIONS: Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00285376.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The role of serotonin receptor subtypes in treating depression: a review of animal studies
Carr, G. V., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2097-z · Cited by 260
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480990 · Cited by 69
“…studies as reported in a 2011 FDA meta-analysis of antidepressant trials (Khin et al., 2011), and somewhat larger than the 1.6–1.8 point HAM-D difference observed for the pivotal studies for the most recently FDAapproved antidepressant, vilazodone (Khan et al., 2011; Rickels et al., 2009).”
ResultInfluentialFava, M., Targum, S. D., Nierenberg, A. A., Bleicher, L. S., Carter, T. A., Wedel, P. C., Hen, R., Gage, F. H., & Barlow, C. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.013 · Cited by 67
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Metadata
- Authors
- Rickels, K., Athanasiou, M., Robinson, D. S., Gibertini, M., Whalen, H., & Reed, C. R.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-03-10
- Volume
- 70
- Issue
- 3
- Pages
- 326-333
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2103009004
- Cited by
- 146
- References
- 0
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.08m04637
- The paper
- Rickels, K., Athanasiou, M., Robinson, D. S., Gibertini, M., Whalen, H., & Reed, C. R. (2009). Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.08m04637
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.